1page img1 jpg
Gamma Vaccines’ lead product is GammaFlu® that offers broader spectrum immunity to different influenza viruses. Gamma Vaccines technology provides significant opportunities for the animal health vaccines market as well as the potential to create improved seasonal flu vaccines for human use. The Company has an innovative pipeline of additional gamma-irradiated vaccines that provide protection against other important veterinary pathogens.
Gamma Vaccines manufactures and kills influenza virus in a manner that preserves the proper structure of the virus and its various proteins. By using gamma irradiation – a procedure in wide-spread use to sterilize surgical instruments and stop spoilage of perishable fruits – a killed virus preparation can be obtained that is no longer infectious and which induces a potent immunity to different influenza virus strains and subtypes.

About

Gamma Vaccines Pty Ltd is an Australian company targeting primarily the human and avian influenza market.

Formed in July 2009, the company is developing a cross-protective influenza virus vaccine, GammaFlu®, designed to replace current seasonal injectable flu vaccines with an easy-to-administer, broader-spectrum intranasal vaccine. The Company’s products also hold the prospect of being able to be stockpiled for use as an immediate first response to any new influenza pandemic. In addition, Gamma Vaccines is developing a vaccine that can provide better protection against highly pathogenic avian influenza in poultry. The Company is also conducting research on vaccines for preventing bacterial pneumonia.

Gamma Vaccines’ proprietary technology was invented by leading researchers from The Australian National University’s John Curtin School of Medical Research and The University of Adelaide’s School of Molecular Life Sciences. The company has attracted significant equity investments from Australian, Indonesian & US investors and been awarded numerous grants from the Australian Capital Territory and the Commonwealth Government of Australia.

Founded by experienced early-stage managers and the inventors themselves, the company is currently negotiating with several partners in Asia and Europe to commence clinical trials for applications in both human and animal vaccination markets.

Recent News

  • TECHINSA Grant Awarded to GPN Vaccines| 17 December 2017THE SOUTH AUSTRALIAN EARLY COMMERCIALISATION FUND ADMINISTERED BY TECHINSA AWARDS GPN VACCINES $300,000.
  • NHMRC Development Grant Awarded to GPN Vaccines| 11 October 2017THE NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL OF AUSTRALIA AWARDS $955,000 TO THE UNIVESITY OF ADELAIDE & GPN VACCINES TO DEVELOP A UNIVERSAL PNEUMOCOCCAL VACCINE
  • GPN Vaccines Incorporated| 19 September 2017GAMMA VACCINES CREATES GPN VACCINES PTY LTD AS VEHICLE TO DEVELOP ITS UNIVERSAL PNEUMOCOCCAL VACCINE [Download]
  • New Director Appointed| 19 September 2017GAMMA VACCINES APPOINTS DR ALAN IRVING AS A NON-EXECUTIVE DIRECTOR
  • New Director Appointed| 1 June 2017GAMMA VACCINES APPOINTS MR HUGH CRAWFORD AS A NON-EXECUTIVE DIRECTOR
  • Publication in Vaccine| 15 February 2017PUBLICATION IN VACCINE OF A STUDY ON THE IMPACT OF GAMMA IRRADIATION ON THE IMMUNOGENICITY OF INACTIVATED INFLUENZA VACCINES
Read More
 

Gamma Vaccines Pty Ltd © 2010 - 2018. Privacy Policy | Designed by GreenDot Pty Ltd & Clearpath |Sitemap